Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
King's Thrombosis Centre COVID-19 Research
Clinicians and researchers in the King’s Thrombosis Centre are completing a number of research studies relating to the COVID-19 pandemic.
Click here to view the latest publications from our centre, relating to this.
Click here to view the BBC interview with Prof Roopen Arya on thrombosis in COVID-19.
VTE EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click here to access the site.
Latest News
-
Anticoagulation news items. Week commencing 16th May 2022
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study The Lancet Infectious DiseasesStudy (n=909 473; 32 329 hospitalised) found occurrence of venous thromboembolism in patients…
-
Anticoagulation news items. Weeks commencing 2nd and 9th May 2022
Association of bleeding severity with mortality in extended thromboprophylaxis of medically ill patients in the MAGELLAN and MARINER trials CirculationPost hoc analysis of rivaroxaban studies found all-cause mortality (ACM) for…
-
Anticoagulation news items. Week commencing 25th April 2022
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism Journal of Thrombosis and HaemastasisStudy (n=8246) found reduced bleeding with rivaroxaban (R) vs enoxaparin/VKA…
